Comparative Pharmacology
Head-to-head clinical analysis: BAXDELA versus CIPROFLOXACIN AND DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAXDELA versus CIPROFLOXACIN AND DEXAMETHASONE.
BAXDELA vs CIPROFLOXACIN AND DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BAXDELA (delafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
Oral: 450 mg (as single tablet) twice daily for 5 days. Intravenous: 450 mg once daily (over 3 hours) or 300 mg twice daily (over 1 hour) for 5 days.
4 drops into affected ear(s) twice daily for 7 days. Otic suspension; shake well before use.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours in healthy adults; may be prolonged in patients with renal impairment (up to 20 hours in severe renal impairment).
Ciprofloxacin: 3.7-4.3 hours (prolonged in renal impairment). Dexamethasone: 3-4 hours.
Renal (approximately 65% of dose as unchanged drug) and fecal (approximately 20% as metabolites and unchanged drug). Biliary excretion is minimal.
Ciprofloxacin: 50-70% unchanged in urine via glomerular filtration and tubular secretion; 20-35% in feces via biliary and intestinal secretion. Dexamethasone: primarily metabolized, <10% unchanged in urine; biliary/fecal excretion of metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic